Cipla awarded USD 188.95mn tender by Global Fund for ARV drugs

Drug major Cipla has been awarded USD 188.95 million (over Rs 1,170 crore) tender for anti- retrovirals drugs for treatment of HIV/AIDS by Global Fund which would enable it to supply the medicines to over 140 countries.
Cipla has been selected as a panel supplier under a supplier partnership agreement.
The contract is effective from the January 1, 2015 and will run for a period of three years. The supplies will begin from the fourth quarter of fiscal year 2015, Cipla said in a statement.
Commenting on the development, Cipla MD & Global CEO Subhanu Saxena said: "We are extremely proud to have won this tender from Global Fund. Cipla has been committed to the cause of HIV/AIDS for over two decades and this tender offers us a great opportunity to make HIV/AIDS treatment accessible to more than 140 countries through Global Fund."

The anti-retrovirals drugs will be manufactured in the company's manufacturing facilities in India, which have been approved by various international regulatory agencies, Cipla said.
Cipla has a long-term association with Global Fund since 2002. Last year, Cipla has been one of the suppliers which was awarded with a long-term contract for supplying anti-malarial drugs, it added.
Global Fund is a 21st century partnership designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics.
Programmes supported by it have put 7.3 million people on antiretroviral therapy for HIV, have tested and treated 12.3 million people for TB, and have distributed 450 million mosquito nets to protect families against malaria.